

A new antioxidant formulation reduces the apoptotic and damaging effect of cigarette smoke extract on human bronchial epithelial cells

L. VANELLA¹, G. LI VOLTI², A. DISTEFANO¹, M. RAFFAELE¹, V. ZINGALES¹, R. AVOLA², D. TIBULLO², I. BARBAGALLO¹

¹Department of Drug Science, Biochemistry Section, University of Catania, Catania, Italy

²Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy

Luca Vanella and Giovanni Li Volti contributed equally to this manuscript

Abstract. – **OBJECTIVE:** In this study we evaluated the possible protective effect of an antioxidant formulation containing microfiltered milk derived polypeptides, Curcumin, Vitamin B2, Carnitine and N-Acetyl-cysteine (NAC) in an *in vitro* model of chronic obstructive pulmonary disease (COPD).

MATERIALS AND METHODS: Human bronchial epithelial cells (16HBE) were used in this study. Cells were treated for 24 h in the presence or absence of 10% of cigarette smoke extract (CSE) and in the presence or absence of antioxidant formulation. We evaluated cell viability by MTT assay, reactive oxygen species by flow cytometer and quantitative analysis of gene expression by Real-time PCR.

RESULTS: The data obtained showed a significant increase of cell viability in CSE-exposed cells and a significant reduction of reactive oxygen species (ROS) production compared to cells treated with only CSE. The antioxidant effects of formulation were confirmed by a decrease of inflammatory cytokines genes IL-1 β , IL-6, TNF α , nitric oxide synthase gene (NOS2) and through an induction of antioxidant genes such as heme oxygenase 1 (HO-1), nuclear transcription factor erythroid 2 (NRF2) and peroxisome proliferator-activated receptor gamma co-activator-1 alpha (PGC-1 α).

CONCLUSIONS: The results suggest that antioxidants combination plays a protective role on oxidative stress and inflammation, in an *in vitro* model of COPD, activating key genes in response to oxidative stress and decreasing the cytokines responsible for the inflammatory pathways.

Key Words:

Antioxidants, Heme oxygenase, Inflammation, COPD.

Introduction

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease characterized by airflow limitation, with a high morbidity and mortality. Epidemiological studies have shown that smoking is the most important pathogenic factor of human COPD ranking fourth in the cause of mortality worldwide^{1,2}.

The airflow limitation is frequently gradual and correlated with an irregular inflammatory response of the lung to noxious particles or gases³. Smoking cigarettes is the principal cause of COPD, but other causes might increase the risk of disease in non-smokers such as maternal smoking, childhood asthma and respiratory infections, previous tuberculosis, outdoor air pollution, exposure to second-hand smoke and genetic cause^{4,5}.

Cigarette smoke contains oxidant molecules, such as hydrogen peroxide, peroxyxynitrate and peroxyxynitrite⁶, leading to airway epithelial cells injury, neutrophils, macrophages and lymphocytes recruitment⁷. Reactive oxygen species (ROS) represent one of the key pathophysiological triggers in the above-described mechanisms, and are responsible for parenchymal injury, if not sufficiently counterbalanced by antioxidant factors⁸.

Previous studies showed that various antioxidant agents, dietary natural product-derived polyphenols and endogenous antioxidant scavenging systems, can scavenge free radicals and oxidants, regulate the expression of redox and glutathione

biosynthesis genes, chromatin remodeling, and inflammatory gene expression^{9,10-14}.

In this work we evaluated the effect of a commercially available formulation (React-On, Thompson Ltd., Rome, Italy), containing micro-filtered milk derived polypeptides, Curcumin, Vitamin B2, Carnitine and N-Acetyl-cysteine (NAC)¹⁵⁻²¹, in epithelial bronchial cell line exposed to smoke cigarette extract.

Materials and Methods

Cell Cultures

Human bronchial epithelial cells (16HBE) were purchased from ATCG. The cells were maintained in culture Dulbecco's Modified Eagle Medium (DMEM) (Gibco, Rockville, MD, USA), supplemented with 10% of fetal bovine serum (FBS) (Gibco), 0.5% gentamycin (Gibco, Rockville, MD, USA), 1% glutamine (Gibco, Rockville, MD, USA) and incubated in a humidified atmosphere of 5% CO₂ at 37°C. 16HBE cells were treated for 24 h in the presence or absence of cigarette smoke extract (CSE), respectively with "React-On" (100 µg/ml), Carnitine (1 mM), Curcumin (5 µM), Vitamin B2 (200 µM), N-Acetyl Cysteine (NAC 1 mM).

Preparation of Cigarette Smoke Extract (CSE)

For the *in vitro* studies we used cigarettes containing 10 mg of tar, 0.7 mg nicotine and 10 mg of carbon monoxide per cigarette. The derived-cigarette smoke was bubbled through a vacuum pump in 10 ml of phosphate buffered saline (PBS). The obtained solution was filtered through a 0.22 µm filter and then diluted to be used in each experiment. The concentration of CSE used in the different experiments was equal to 20%, 10%, 5% and 2.5% of the final volume used for each assay.

Measurement of Cell Viability

Cells were cultured in 96-well plates and treated for 24 h with different concentrations of CSE, respectively 20%, 10%, 5% and 2.5% and subsequently with React-On (100 µg/ml), Carnitine (1 mM), Curcumin (5 µM), Vitamin B2 (200 µM), N-Acetyl Cysteine (NAC 1 mM) in the presence or absence of 10% CSE. Successively, the medium was replaced by a solution containing bromide 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) and incubated for 3 h at 37°C. Finally, it was added dimethylsulfoxide (DMSO) to all wells and the plate was read in a spectrophotometer at λ 570 nm.

Measurement of Reactive Oxygen Species (ROS)

Reactive oxygen species formation (ROS) was determined cytofluorimetrically using the MUSE Oxidative Stress kit (Millipore, Billerica, MA, USA). Briefly, 10 µl of cell suspension in 1X Muse assay buffer was added to 190 µL of working solution reagent MUSE[®] oxidative stress. The samples were vortexed for 3-5 s and then incubated for 30 min at 37°C, subsequently read by Muse[™] Cell Analyzer (Millipore, Billerica, MA, USA).

RNA Extraction and Real-Time PCR

Trizol reagent (Life Technology, Milan, Italy) was used to extract total RNA. The extracted mRNA was subsequently converted into cDNA through a kit containing the reverse transcription (Life Technology, Milan, Italy). The quantitative analysis was performed using the One-Step Real-time PCR instrument using the SYBR Green PCR master mix (Life Technology, Milan, Italy). The primer sequences are shown in Table I. The level of expression of its mRNA was calculated using the comparative method $\Delta\Delta C_t$ -2 as previously described²²⁻²⁴.

Table I. PCR primers used.

Gene	Primer Forward	Primer Reverse
HO-1	GTGCCACCAAGTTCAAGCAG	CACGCATGGCTCAAAAACCA
GAPDH	AGACACCATGGGGAAGGTGA	TGGAATTTGCCATGGGTGGA
IL-1β	ATGATGGCTTATTACAGTGGCAA	GTCGGAGATTCGTAGCTGGA
IL-6	GAAAGCAGCAAAGAGGCACT	TTTACCAGGCAAGTCTCCT
NRF2	TCAGCGACGGAAAGAGTATGA	CCACTGGTTTCTGACTGGATGT
PGC1α	GGTGCAGTTTGGCAAGGAG	TTCCTTGGGGTCCAGACAGA
NOS2	TTCAGTATCACAACCTCAGCAAG	TGGACCTGCAAGTTAAATCCC
TNFα	AAGCACACTGGTTTCCACACT	TGGGTCCCTGCATATCCGTT

Statistical Analysis

Data were presented as mean \pm standard deviation (SD) of $n=4$ experiments performed in triplicate. The statistical significance ($p < 0.05$) of differences between experimental groups was determined by analysis of t -test. Newman-Keuls Post hoc test was used to validate ANOVA.

Results

Effect of CSE on Cell Viability

In order to estimate preliminarily the concentration of CSE to be used, a viability test was performed respectively with 20%, 10%, 5% and 2.5% of CSE for 24 h. These set of experiments showed a significant decrease in cell viability following 20% and 10% CSE treatment (Figure 1) ($p < 0.05$). Therefore, we used a concentration of 10% of CSE for all the following experiments.

React-On Effect on Cell Viability

To evaluate the effects of React-on following exposure to CSE, cells were treated in the presence and absence of 100 $\mu\text{g/ml}$ of React-On for 24 h. In addition, the effects on cell viability of different components of the React-On formulation as Curcumin, Carnitine, NAC and vitamin B2, were evaluated. Surprisingly, React-On was the only treatment conferring protection to cells from the cytotoxic effects of CSE (Figure 2). In fact, our results showed a significant increase in cell viability compared to cells treated with only CSE ($p < 0.05$).




Figure 1. Viability assay measured by MTT assay after 24 h of treatment. CSE = cigarette smoke extract. * $p < 0.05$ to CTRL.




Figure 2. Viability assay measured by MTT assay after 24 h of treatment. * $p < 0.05$ to CTRL; ** $p < 0.05$ to CSE.

Measuring the Formation of Reactive Oxygen Species

Figure 3 shows the results of ROS measurement. In particular, our results showed that ROS formation is induced by CSE ($p < 0.05$) and that treatment with React-On was able to decrease ROS levels ($p < 0.05$), demonstrating a protective effect from oxidative stress induced by CSE.

Expression of Cytokine Genes IL-1 β , IL-6 and TNF α

In order to assess the grade of inflammation caused by CSE, we evaluated the expression of pro-inflammatory cytokine genes, interleukin 1 β (IL-1 β), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF α). Figure 4 shows that CSE treatment was able to increase cytokines gene levels ($p < 0.05$ for all cytokines) whereas treatment with CSE and React-on led to a decrease of IL-1 β , IL-6 and TNF α gene expression ($p < 0.05$).

React-On Induces HO-1, NRF2, PGC-1 α and Reduces iNOS Gene Expression

Figure 5 shows that CSE and React On cotreatment were able to increase heme oxygenase-1 (HO-1) and transcription factor nuclear factor erythroid-2 (NRF2) genes levels, compared to CSE treatment alone. Moreover, cotreatment with React-On and CSE resulted in a decrease of inducible nitric oxide synthase gene (NOS2 or iNOS) and a significant increase of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 α).

Effect antioxidant formulation on apoptotic damage of CES on 16 HBE cells




Figure 3. Effect of CSE and React-On on the ROS production analyzed by flow cytometric assay. * $p < 0.05$ to CTRL; ** $p < 0.05$ to CSE.




Figure 4. Effect of CSE and React-On on cytokines genes IL-1 β , IL-6 and TNF α analyzed by Real-time PCR. * $p < 0.05$ to CTRL; ** $p < 0.05$ to CSE




Figure 5. Effect of CSE and React-On on HO-1, NRF2, PGC-1 α and iNOS gene expression analyzed by Real-time PCR. * $p < 0.05$ to CTRL; ** $p < 0.05$ to CSE.

Discussion

In this study we evaluated the possible protective capacity of React-On in an *in vitro* model of chronic obstructive pulmonary disease (COPD), emphysema and chronic bronchitis, reproducing the bronchial epithelium exposed to cigarette smoke^{25,26}. From the data collected and consistently with previous studies, it appears that the administration, *in vitro*, of a medium containing a cigarette smoke extract was able to reduce significantly cell viability, increasing both ROS formation and inflammatory cytokines levels, such as IL-1 β , IL-6 and TNF α ^{27,28}.

The React-On formulation contains, in addition to polypeptides of microfiltered milk, Curcumin, Vitamin B2, Carnitine and NAC. These molecules are frequently present as metabolic co-factors having an important function in response to oxidative stress¹⁰⁻¹³.

In our investigations, the above substances were also analyzed individually, in order to obtain a comparative analysis with the complete formulation.

The results, obtained after the treatment with React-On, Curcumin, Vitamin B2, Carnitine and NAC, surprisingly reveal that React-On was the only treatment able to significantly restore cell viability in CSE exposed cells. Consequently, we investigated the effect of React-On on oxidative stress induced by CSE. In this regard, the formation of ROS was measured following treatment with React-On in the presence or absence of the CSE. The data obtained showed that React-On was able to significantly reduce the production of ROS compared to cells treated with only CSE, confirming the reduction of oxidative stress induced by the product.

In order to assess the biochemical mechanism by which React-On reduces oxidative stress, it was examined the expression of HO-1 and NRF2 genes. It has been shown previously, that the expression of these genes is essential in characterizing the endogenous pathway response of cells to oxidative stress²⁹⁻³⁴. React-On was able to increase both genes, suggesting that the decrease of oxidative stress, observed in our results, is mediated by the induction of these genes and HO-

1 enzymatic activity^{33,34}. Also, treatment with React-On following CSE exposure was able to decrease the expression of these genes confirming an anti-inflammatory role of this product. Noteworthy, our data showed that React-On induced peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 α) gene, which is a marker of mitochondrial biogenesis and its overexpression is associated to an increased energy production, fundamental for the cellular antioxidant response³⁵.

Conclusions

React-On plays a protective role on oxidative stress and inflammation in an *in vitro* model of COPD, emphysema and chronic bronchitis by reducing the formation of ROS, activating key genes in response to oxidative stress and to decrease the cytokine responsible for the inflammatory pathway.

Conflict of Interest

The Authors declare that they have no conflict of interests.

References

- 1) DECRAMER M, JANSSENS W, MIRAVITLES M. Chronic obstructive pulmonary disease. *Lancet* 2012; 379: 1341-1351.
- 2) SIN DD. Therapeutic options for chronic obstructive pulmonary disease: present and future. *Eur Rev Med Pharmacol Sci* 2004; 8: 247-258.
- 3) RABE KF, HURD S, ANZUETO A, BARNES PJ, BUIST SA, CALVERLEY P, FUKUCHI Y, JENKINS C, RODRIGUEZ-ROISIN R, VAN WEEL C, ZIELINSKI J, GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG D. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 2007; 176: 532-555.
- 4) EISNER MD, ANTHONISEN N, COULTAS D, KUENZLI N, PEREZ-PADILLA R, POSTMA D, ROMIEU I, SILVERMAN EK, BALMES JR, COMMITTEE ON NONSMOKING COPD E, OCCUPATIONAL HEALTH A. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2010; 182: 693-718.
- 5) MARTINEZ FD. Early-life origins of chronic obstructive pulmonary disease. *N Engl J Med* 2016; 375: 871-878.
- 6) PRYOR WA, STONE K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxyxynitrate, and peroxyxynitrite. *Ann N Y Acad Sci* 1993; 686: 12-27.
- 7) PAONE G, CONTI V, LEONE A, SCHMID G, PUGLISI G, GIANNUNZIO G, TERZANO C. Human neutrophil peptides sputum levels in symptomatic smokers and COPD patients. *Eur Rev Med Pharmacol Sci* 2011; 15: 556-562.
- 8) LARSSON K. Aspects on pathophysiological mechanisms in COPD. *J Intern Med* 2007; 262: 311-340.
- 9) BISWAS S, HWANG JW, KIRKHAM PA, RAHMAN I. Pharmacological and dietary antioxidant therapies for chronic obstructive pulmonary disease. *Curr Med Chem* 2013; 20: 1496-1530.
- 10) BALOGUN E, HOQUE M, GONG P, KILLEEN E, GREEN CJ, FORESTI R, ALAM J, MOTTERLINI R. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. *Biochem J* 2003; 371: 887-895.
- 11) ASHOORI M, SAEDISOMEOLIA A. Riboflavin (vitamin B(2)) and oxidative stress: a review. *Br J Nutr* 2014; 111: 1985-1991.
- 12) MATE A, MIGUEL-CARRASCO JL, VAZQUEZ CM. The therapeutic prospects of using L-carnitine to manage hypertension-related organ damage. *Drug Discov Today* 2010; 15: 484-492.
- 13) MATERA MG, CALZETTA L, CAZZOLA M. Oxidation pathway and exacerbations in COPD: the role of NAC. *Expert Rev Respir Med* 2016; 10: 89-97.
- 14) LI VOLTI G, SALOMONE S, SORRENTI V, MANGIAMELI A, URSO V, SIARKOS I, GALVANO F, SALAMONE F. Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice. *Cardiovasc Diabetol* 2011; 10: 62.
- 15) YILMAZ Y, TAKEN K, ATAR M, ERGUN M, SOYLEMEZ H. Protective effect of curcumin on priapism and ischemia-reperfusion injury in rats. *Eur Rev Med Pharmacol Sci* 2015; 19: 4664-4670.
- 16) ZHANG YJ, XIANG H, LIU JS, LI D, FANG ZY, ZHANG H. Study on the mechanism of AMPK signaling pathway and its effect on apoptosis of human hepatocellular carcinoma SMMC-7721 cells by curcumin. *Eur Rev Med Pharmacol Sci* 2017; 21: 1144-1150.
- 17) RIVA A, TOGNI S, GIACOMELLI L, FRANCESCHI F, EGGENHOFFNER R, FERAGALLI B, BELCARO G, CACCHIO M, SHU H, DUGALL M. Effects of a curcumin-based supplementation in asymptomatic subjects with low bone density: a preliminary 24-week supplement study. *Eur Rev Med Pharmacol Sci* 2017; 21: 1684-1689.
- 18) PAN ZJ, DENG N, ZOU ZH, CHEN GX. The effect of curcumin on bladder tumor in rat model. *Eur Rev Med Pharmacol Sci* 2017; 21: 884-889.
- 19) KOKSAL M, KURCER Z, ERDOGAN D, IRAZ M, TAS M, EREN MA, AYDOGAN T, ULAS T. Effect of melatonin and n-acetylcysteine on hepatic injury in rat induced by methanol intoxication: a comparative study. *Eur Rev Med Pharmacol Sci* 2012; 16: 437-444.

- 20) BOLOGNESI G, BELCARO G, FERAGALLI B, CORNELLI U, COTTELESE R, HU S, DUGALL M. Movardol(R) (N-acetylglucosamine, Boswellia serrata, ginger) supplementation in the management of knee osteoarthritis: preliminary results from a 6-month registry study. *Eur Rev Med Pharmacol Sci* 2016; 20: 5198-5204.
- 21) NORDIO M. A novel treatment for subclinical hyperthyroidism: a pilot study on the beneficial effects of l-carnitine and selenium. *Eur Rev Med Pharmacol Sci* 2017; 21: 2268-2273.
- 22) BARBAGALLO I, PARENTI R, ZAPPALA A, VANELLA L, TIBULLO D, PEPE F, ONNI T, LI VOLTI G. Combined inhibition of Hsp90 and heme oxygenase-1 induces apoptosis and endoplasmic reticulum stress in melanoma. *Acta Histochem* 2015; 117: 705-711.
- 23) PALMERI R, MONTELEONE JI, SPAGNA G, RESTUCCIA C, RAFFAELE M, VANELLA L, LI VOLTI G, BARBAGALLO I. Olive leaf extract from sicilian cultivar reduced lipid accumulation by inducing thermogenic pathway during adipogenesis. *Front Pharmacol* 2016; 7: 143.
- 24) SALERNO L, PITTALA V, ROMEO G, MODICA MN, SIRACUSA MA, DI GIACOMO C, ACOUAVIVA R, BARBAGALLO I, TIBULLO D, SORRENTI V. Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties. *Bioorg Med Chem* 2013; 21: 5145-5153.
- 25) DING S, HOU X, YUAN J, TAN X, CHEN J, YANG N, LUO Y, JIANG Z, JIN P, DONG Z, FENG L, JIA X. Wedelolactone protects human bronchial epithelial cell injury against cigarette smoke extract-induced oxidant stress and inflammation responses through Nrf2 pathway. *Int Immunopharmacol* 2015; 29: 648-655.
- 26) CORRAO S, ANZALONE R, LO IACONO M, CORSELLO T, DI STEFANO A, D'ANNA SE, BALBI B, CARONE M, SALLA A, CORONA D, TIMPERIO AM, ZOLLA L, FARINA F, DE MACARIO EC, MACARIO AJ, CAPPELLO F, LA ROCCA G. Hsp10 nuclear localization and changes in lung cells response to cigarette smoke suggest novel roles for this chaperonin. *Open Biol* 2014; 4: pii: 140125.
- 27) WU H, YANG S, WU X, ZHAO J, ZHAO J, NING Q, XU Y, XIE J. Interleukin-33/ST2 signaling promotes production of interleukin-6 and interleukin-8 in systemic inflammation in cigarette smoke-induced chronic obstructive pulmonary disease mice. *Biochem Biophys Res Commun* 2014; 450: 110-116.
- 28) LIU MH, LIN AH, LU SH, PENG RY, LEE TS, KOU YR. Eicosapentaenoic acid attenuates cigarette smoke-induced lung inflammation by inhibiting ROS-sensitive inflammatory signaling. *Front Physiol* 2014; 5: 440.
- 29) COMANDINI A, MARZANO V, CURRADI G, FEDERICI G, URBANI A, SALTINI C. Markers of anti-oxidant response in tobacco smoke exposed subjects: a data-mining review. *Pulm Pharmacol Ther* 2010; 23: 482-492.
- 30) KENSLE TW, WAKABAYASHI N, BISWAL S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. *Annu Rev Pharmacol Toxicol* 2007; 47: 89-116.
- 31) NING W, LI CJ, KAMINSKI N, FEGHALI-BOSTWICK CA, ALBER SM, DI YP, OTTERBEIN SL, SONG R, HAYASHI S, ZHOU Z, PINSKY DJ, WATKINS SC, PILEWSKI JM, SCIURBA FC, PETERS DG, HOGG JC, CHOI AM. Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. *Proc Natl Acad Sci U S A* 2004; 101: 14895-14900.
- 32) BARBAGALLO I, NICOLOSI A, CALABRESE G, DAVID S, CIMINO S, MADONIA M, CAPPELLO F. The role of the heme oxygenase system in the metabolic syndrome. *Curr Pharm Des* 2014; 20: 4970-4974.
- 33) TIBULLO D, BARBAGALLO I, GIALLONGO C, LA CAVA P, PARINELLO N, VANELLA L, STAGNO F, PALUMBO GA, LI VOLTI G, DI RAIMONDO F. Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells. *Curr Pharm Des* 2013; 19: 2765-2770.
- 34) SACERDOTI D, COLOMBRITA C, GHATTAS MH, ISMAEL EF, SCAPAGNINI G, BOLOGNESI M, LI VOLTI G, ABRAHAM NG. Heme oxygenase-1 transduction in endothelial cells causes downregulation of monocyte chemoattractant protein-1 and of genes involved in inflammation and growth. *Cell Mol Biol (Noisy-le-grand)* 2005; 51: 363-370.
- 35) AUSTIN S, ST-PIERRE J. PGC1alpha and mitochondrial metabolism--emerging concepts and relevance in ageing and neurodegenerative disorders. *J Cell Sci* 2012; 125: 4963-4971.